AY1AX000001
Cooperative Agreement
Overview
Grant Description
CureIT: Curing the uncurable via RNA-encoded immunogene tuning - More than 25 million Americans currently live with autoimmune disease, and almost two million are projected to be diagnosed with cancer in 2023.
Immune dysregulation is an underlying component of not only cancer and autoimmune diseases, but also infectious diseases, transplant rejection, and other common medical conditions.
Current methods of immune modulation used to treat and mitigate these conditions are often expensive or not completely effective.
Curing the uncurable via RNA-encoded immunogene tuning (CureIT) aims to address immune dysregulation by directly programming immune cell function.
Advances in gene-encoded technology will be leveraged to develop a platform capability able to both enhance protective immune responses as well as modulate insufficient or ineffective immune profiles.
CureIT seeks to develop a disease-agnostic toolbox of methods and technologies, including the in vivo delivery of mRNA-based drugs, cell targeting lipid nanoparticles, and ex vivo modulation of immune cells.
This technology has the potential to make significant advancements towards managing or eliminating many diseases and conditions affecting all ages and demographics, including diseases which are currently untreatable.
Immune dysregulation is an underlying component of not only cancer and autoimmune diseases, but also infectious diseases, transplant rejection, and other common medical conditions.
Current methods of immune modulation used to treat and mitigate these conditions are often expensive or not completely effective.
Curing the uncurable via RNA-encoded immunogene tuning (CureIT) aims to address immune dysregulation by directly programming immune cell function.
Advances in gene-encoded technology will be leveraged to develop a platform capability able to both enhance protective immune responses as well as modulate insufficient or ineffective immune profiles.
CureIT seeks to develop a disease-agnostic toolbox of methods and technologies, including the in vivo delivery of mRNA-based drugs, cell targeting lipid nanoparticles, and ex vivo modulation of immune cells.
This technology has the potential to make significant advancements towards managing or eliminating many diseases and conditions affecting all ages and demographics, including diseases which are currently untreatable.
Awardee
Funding Goals
THE PURPOSE OF THIS PROGRAM IS TO COORDINATE THE ACCELERATION OF BIOMEDICAL AND HEALTH BREAKTHROUGHS TO DELIVER TRANSFORMATIVE, SUSTAINABLE, AND EQUITABLE HEALTH SOLUTIONS FOR EVERYONE BY (A) FACILITATING COLLABORATION BETWEEN ADVANCE RESEARCH PROJECTS AGENCY FOR HEALTH AND OTHER FEDERAL AGENCIES, RELEVANT INDUSTRIES, ACADEMIA, AND OTHER PERSONS, WITH RESPECT TO ADVANCE HIGH-POTENTIAL, HIGH IMPACT BIOMEDICAL AND HEALTH RESEARCH THAT CANNOT BE READILY ACCOMPLISHED THROUGH TRADITIONAL RESEARCH AND COMMERCIAL ACTIVITY, (B) IDENTIFYING AND PROMOTING REVOLUTIONARY ADVANCED IN HEALTH SCIENCES, (C) PROMOTING HIGH REWARD INNOVATION TO DEVELOP HIGH NEED CURES (D) ENSURING THAT THE UNITED STATES MAINTAINS, GLOBAL LEADERSHIP AND SCIENCE AND INNOVATION AND THE HIGHEST QUALITY OF LIFE AND HEALTH FOR ITS CITIZENS.
Grant Program (CFDA)
Awarding / Funding Agency
Place of Performance
Georgia
United States
Geographic Scope
State-Wide
Related Opportunity
Emory University was awarded
Advancing Immune Cell Function: CUREIT RNA-Encoded Immunogene Tuning
Cooperative Agreement AY1AX000001
worth $24,754,589
from the National Institutes of Health in August 2023 with work to be completed primarily in Georgia United States.
The grant
has a duration of 3 years and
was awarded through assistance program 93.384 ADVANCED RESEARCH PROJECTS AGENCY for HEALTH (ARPA-H).
The Cooperative Agreement was awarded through grant opportunity ARPA-H Open Office BAA.
Status
(Ongoing)
Last Modified 5/5/25
Period of Performance
8/23/23
Start Date
8/22/26
End Date
Funding Split
$24.8M
Federal Obligation
$0.0
Non-Federal Obligation
$24.8M
Total Obligated
Activity Timeline
Subgrant Awards
Disclosed subgrants for AY1AX000001
Transaction History
Modifications to AY1AX000001
Additional Detail
Award ID FAIN
AY1AX000001
SAI Number
AY1AX000001-4049571707
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
Private Institution Of Higher Education
Awarding Office
75N992 ADVANCED RESEARCH PROJECTS AGENCY FOR HEALTH (ARPA-H)
Funding Office
75N992 ADVANCED RESEARCH PROJECTS AGENCY FOR HEALTH (ARPA-H)
Awardee UEI
S352L5PJLMP8
Awardee CAGE
2K291
Performance District
GA-90
Senators
Jon Ossoff
Raphael Warnock
Raphael Warnock
Budget Funding
| Federal Account | Budget Subfunction | Object Class | Total | Percentage |
|---|---|---|---|---|
| Advanced Research Projects Agency for Health-NIH, National Institutes of Health, Department of Health and Human Services (075-0837) | Health research and training | Grants, subsidies, and contributions (41.0) | $24,754,589 | 100% |
Modified: 5/5/25